GlassScriptPhysician profile
Kristi A Johnson
NPI 1023099298
$1,197.08
in general payments reported to CMS, 2019-2025
23 companies · $317 in 2025
The $317 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $89.17 · 2020: $40.25 · 2021: $165 · 2022: $302 · 2023: $109 · 2024: $174 · 2025: $317.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $600.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $600.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $148.28 | 2025 | Rezdiffra |
| Astellas Pharma US INC | $124.85 | 2024 | Veozah |
| Pfizer INC. | $106.29 | 2022-2025 | |
| Abbvie INC. | $105.18 | 2019-2020 | |
| Mylan Pharmaceuticals INC. | $81.46 | 2021-2022 | |
| Sage Therapeutics, LLC | $80.73 | 2025 | Zurzuvae |
| Exeltis, USA INC. | $71.63 | 2021-2025 | Slynd |
| Mayne Pharma Commercial LLC | $59.20 | 2022-2023 | |
| Therapeuticsmd, INC. | $57.71 | 2021-2022 | |
| Agile Therapeutics, INC. | $52.62 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $52.61 | 2019-2021 | |
| Exact Sciences Corporation | $34.68 | 2023-2024 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $32.40 | 2023-2025 | Myfembree, Gemtesa |
| Vanda Pharmaceuticals INC. | $31.61 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $25.02 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $24.92 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.14 | 2023 | Trulance, Xifaxan |
| Janssen Pharmaceuticals, INC | $18.69 | 2025 | Spravato |
| Astrazeneca Pharmaceuticals LP | $15.72 | 2022 | |
| Alkermes, INC. | $13.93 | 2022 | |
| Glaxosmithkline, LLC. | $13.92 | 2022 | |
| Sunovion Pharmaceuticals INC. | $12.80 | 2022 | |
| Lilly USA, LLC | $12.69 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristi Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.